Alzheimer's Disease Research Today is a free monthly online journal that collates and summarizes the latest research about Alzheimer's Disease, including details on diagnosis, memory loss, heredity, treatment, medication.

Genotype-related changes of ganglioside composition in brain regions of transgenic mouse models of Alzheimer's disease.

Barrier L, Ingrand S, Damjanac M, Rioux Bilan A, Hugon J, Page G

Groupe de Recherche sur le Vieillissement Cérébral, GReViC EA 3808, Faculté de Médecine et de Pharmacie, 34, rue du Jardin des Plantes, BP 199, 86005 Poitiers Cedex, France. lbarrier@univ-poitiers.fr

In this study, brain gangliosides of different transgenic mouse models of Alzheimer's disease (AD) were analyzed and compared with age-matched wild-type mice. Gangliosides were analyzed in cerebral cortex, a region with extensive A beta plaques, and cerebellum, a non-vulnerable region with no A beta containing plaques. There was a marked increase in simple gangliosides GM2 and GM3 only within the cortex of all mice expressing APP(SL). Additionally, loss of complex "a" gangliosides (GT1a, GD1a and GM1) was recorded in APP/PS1Ki model, whereas in APP(SL) and APP/PS1 mice, the complex "b" gangliosides (GQ1b, GT1b and GD1b) moderately decreased. Surprisingly, expression of either mutant PS1(M146L) or PS1 mutant FAD (Ki model) alone tended to lower the levels of both GM2 and GM3 within the cortex. Conversely, only slight changes of the ganglioside pattern were found in the cerebellum. Because ganglioside alterations occurring in APP transgenic mice were similar to those observed in human AD brain, these transgenic models would represent valuable tools to further investigate the role of altered ganglioside metabolism in the pathogenesis of AD.

Published 23 October 2007 in Neurobiol Aging, 28(12): 1863-72.
Full-text of this article is available online (may require subscription).

© 2004-2008 Alzheimer's Disease Research Today. All Rights Reserved.